Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data [PDF]
, 2022 Introduction. Migraine is one of the most common disabling neurological disorders. Recently developed monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor are the first targeted medication for preventive therapy of both ...
A. M. Uzhakhov +5 more
core +2 more sources
The rationality of recommendations of drugs for patients with cephalgia in simulated situations in the pharmacy [PDF]
, 2022 Relevance. According to statistics of the World Health Organization, at least half of the world’s adult population experienced headaches at least once a year.
A. I. Grishin, O. V. Reshetko
core +2 more sources
Botulin therapy for chronic migraine [PDF]
, 2023 This article presents a review of current modern research on the use of botulinum toxin therapy for the prevention and treatment of patients with chronic migraine, as well as briefly outlines current views on the pathogenesis of migraine, its impact on ...
E. V. Istomina, N. I. Gruzdeva
core +2 more sources
Analysis of the quality of diagnosis and treatment of primary headache in different social groups of the Ural Region [PDF]
, 2015 Objective: to analyze the quality of diagnosis and treatment of primary headache (HA) in different social groups of the Ural Region. Patients and methods. The study enrolled 3124 persons who were divided into three groups: 1) 1042 students; of them there
D. V. Gilev +3 more
core +2 more sources
Особенности фармацевтического консультирования при головной боли [PDF]
, 2020 ГОЛОВНАЯ БОЛЬ /КЛАСС /ЛЕК ТЕРГОЛОВНОЙ БОЛИ СИНДРОМЫ /КЛАСС /ЛЕК ТЕРЛЕКАРСТВА ПЕРВОЙ НЕОБХОДИМОСТИЛЕКАРСТВ ФИЗИОЛОГИЧЕСКОЕ ДЕЙСТВИЕЛЕКАРСТВА, ИНФОРМАЦИОННЫЕ СЛУЖБЫЛЕКАРСТВА, ОТПУСКАЕМЫЕ БЕЗ РЕЦЕПТАЛЕКАРСТВЕННЫЕ ПРЕПАРАТЫ СВОБОДНОЙ ПРОДАЖИПАТЕНТОВАННЫЕ ...
Кугач, В. В. +2 more
core
Innovative drugs for the treatment of primary headaches: migraine [PDF]
, 2019 The article presents information about innovative drugs for the treatment of primary headaches (in particular, migraine), which are at the stages of clinical or preclinical studies, or were recently introduced to the foreign pharmaceutical market.
A. I. Grishin, O. V. Reshetko
core +2 more sources
Клиническая фармакология, фармакологическая терапия [PDF]
, 2015 ПОСОБИЯФАРМАЦИЯФАРМАКОЛОГИЯ КЛИНИЧЕСКАЯЛЕКАРСТВЕННАЯ ТЕРАПИЯПРАКТИЧЕСКИЕ ЗАНЯТИЯВ пособие входят темы лекций и практических занятий по клинической фармакологии с основами фармакотерапии, карта фармакологического анализа, перечень рекомендуемой ...
Антонова, Е. Г. +8 more
core +1 more source
Лечение и профилактика мигрени [PDF]
, 2003 МИГРЕНЬ /ЛЕК ТЕР /ПРОФГОЛОВНАЯ БОЛЬ СОСУДИСТАЯ /ЛЕК ТЕР /ПРОФТРИПТАНЫАНАЛГЕЗИРУЮЩИЕ СРЕДСТВАПРОТИВОВОСПАЛИТЕЛЬНЫЕ СРЕДСТВА ...
Пир, Тфелт-Хансен
core
Classification and some properties of triptans [PDF]
, 2013 Triptans are a group of tryptamine-based drugs used in the acute treatment of migraine headaches. Structurally related to the neurotransmitter serotonin, triptans acts by selectively binding to serotonin type-1D receptors. The present paper submitted the
Antal, Irуna
core
Treatment for chronic daily headache by using auxiliary and alternative methods [PDF]
, 2015 Chronic daily headache (CDH) is one of the top 10 causes of adult disability and one of the 5 most common causes of female disability. To treat patients with CDH is one of the most difficult tasks in neurological practice.
V. A. Golovacheva +2 more
core +2 more sources